Publications
Publishing the Frontiers of Immuno-Oncology
Spotlight Publication
Botensilimab (Fc-enhanced anti-CTLA-4), Balstilimab (PD-1 inhibitor)
Preoperative Botensilimab with or without Balstilimab for Patients with Resectable, Locally Advanced pMMR or dMMR Colon Cancer: the UNICORN Trial by GONO
November 2, 2026
,
Ghelardi, F. et al.
Nature Medicine
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Botensilimab (Fc-enhanced anti-CTLA-4)
Balstilimab (PD-1 inhibitor)
Phase 2 Trial of Botensilimab (Fc-Enhanced Anti–Ctla-4), Balstilimab (Anti–Pd-1) And Doxorubicin Delivered With Ultrasound/Microbubble-Based Blood-Brain Barrier Opening In Newly Diagnosed Mgmt Un-Methylated Glioblastoma: Initial Report
Other Articles & Publications
European Association of Neuro-Oncology
September 25, 2026
,
Sonabend, A et al.
Botensilimab (Fc-enhanced anti-CTLA-4)
Balstilimab (PD-1 inhibitor)
Transcriptomic Profiling Identifies Immunotherapy-Responsive Phenotypes in Microsatellite-Stable Metastatic Colorectal Cancer
Other Articles & Publications
European Conference on Computational Biology
September 2, 2026
,
Konecny, T. et al.
Botensilimab (Fc-enhanced anti-CTLA-4)
Balstilimab (PD-1 inhibitor)
Extended Follow-Up of Botensilimab Plus Balstilimab in an Expanded Cohort of Microsatellite-Stable Metastatic Colorectal Cancer Without Active Liver Metastases
Other Articles & Publications
Clinical Cancer Research
August 28, 2026
,
Schlechter, B. et al.
Botensilimab (Fc-enhanced anti-CTLA-4)
Balstilimab (PD-1 inhibitor)
Neoadjuvant Botensilimab/Balstilimab for localized mismatch repair proficient and deficient colon cancer: Results of the NEST phase 2 clinical trial
Other Articles & Publications
Clinical Cancer Research
August 26, 2026
,
Shah, M. et al.